TY - JOUR
T1 - Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer
T2 - a multi-institutional comparative analysis
AU - Narita, Takuma
AU - Hatakeyama, Shingo
AU - Narita, Shintaro
AU - Takahashi, Masahiro
AU - Sakurai, Toshihiko
AU - Kawamura, Sadafumi
AU - Hoshi, Senji
AU - Shimoda, Jiro
AU - Kawaguchi, Toshiaki
AU - Ishidoya, Shigeto
AU - Mitsuzuka, Koji
AU - Arai, Yoichi
AU - Ito, Akihiro
AU - Tsuchiya, Norihiko
AU - Habuchi, Tomonori
AU - Ohyama, Chikara
N1 - Funding Information:
We would like to thank Itsuto Hamano, Teppei Okamoto, Naoki Fujita, Hiromichi Iwamura, Yuki Fujita, Yukie Nishizawa, and the entire staff of the Department of Urology in Hirosaki University for their invaluable help with the data collection. The authors would also like to thank Editage (www.editage.jp) for the English language review. Funding: This study was supported by Japan Society for the Promotion of Science (JSPS) KAENHI (Grant Numbers of 15H02563, 17K11119, 18K09157, and 19H05556).
Publisher Copyright:
© Translational Andrology and Urology. All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Background: The clinical benefit of the combined androgen blockade (CAB) therapy over luteinizing hormone-releasing hormone analog (LH-RHa) monotherapy for hormone naïve metastatic prostate cancer (mHNPC) is unclear. Therefore, we retrospectively compare the effectiveness of CAB with the LH-RHa monotherapy on the prognosis of Japanese patients with mHNPC. Methods: We retrospectively evaluated the prognosis of 517 patients diagnosed with mHNPC between August 2001 and May 2017. The patients’ data were obtained from the Michinoku Urological Cancer Research Group database and Hirosaki University-related hospitals. Patients were divided into the CAB and LH-RHa monotherapy groups based on primary androgen deprivation therapy (ADT). Overall survival (OS), cancer-specific survival (CSS), and castrate-resistant prostate cancer-free survival (CRPC-FS) were compared between the two groups using the Kaplan-Meier curve analysis. Inverse probability of treatment weighting (IPTW)-adjusted Cox hazard proportional analyses was performed to investigate the effect of primary ADT on oncological outcomes. Results: The median age was 73 years old. The numbers of patients in the CAB and LH-RHa monotherapy groups were 447 and 70, respectively. The Kaplan-Meier curve analysis showed no significant differences in either 5-year OS (56.7% vs. 52.5%, P=0.277), CSS (61.1% vs. 56.4%, P=0.400), and CRPC-FS (33.1% vs. 31.1%, P=0.529) between the groups. IPTW-adjusted multivariate Cox hazard proportional analyses showed no significant differences in OS, CSS, and CRPC-FS between the two groups. Conclusions: No significant differences in oncological outcomes were observed between the CAB and LH-RHa monotherapy groups in patients with mHNPC.
AB - Background: The clinical benefit of the combined androgen blockade (CAB) therapy over luteinizing hormone-releasing hormone analog (LH-RHa) monotherapy for hormone naïve metastatic prostate cancer (mHNPC) is unclear. Therefore, we retrospectively compare the effectiveness of CAB with the LH-RHa monotherapy on the prognosis of Japanese patients with mHNPC. Methods: We retrospectively evaluated the prognosis of 517 patients diagnosed with mHNPC between August 2001 and May 2017. The patients’ data were obtained from the Michinoku Urological Cancer Research Group database and Hirosaki University-related hospitals. Patients were divided into the CAB and LH-RHa monotherapy groups based on primary androgen deprivation therapy (ADT). Overall survival (OS), cancer-specific survival (CSS), and castrate-resistant prostate cancer-free survival (CRPC-FS) were compared between the two groups using the Kaplan-Meier curve analysis. Inverse probability of treatment weighting (IPTW)-adjusted Cox hazard proportional analyses was performed to investigate the effect of primary ADT on oncological outcomes. Results: The median age was 73 years old. The numbers of patients in the CAB and LH-RHa monotherapy groups were 447 and 70, respectively. The Kaplan-Meier curve analysis showed no significant differences in either 5-year OS (56.7% vs. 52.5%, P=0.277), CSS (61.1% vs. 56.4%, P=0.400), and CRPC-FS (33.1% vs. 31.1%, P=0.529) between the groups. IPTW-adjusted multivariate Cox hazard proportional analyses showed no significant differences in OS, CSS, and CRPC-FS between the two groups. Conclusions: No significant differences in oncological outcomes were observed between the CAB and LH-RHa monotherapy groups in patients with mHNPC.
KW - Bicalutamide
KW - Combined androgen blockade (CAB)
KW - Luteinizing hormone-releasing hormone analog (LH-RHa)
KW - Metastatic prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85100310377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100310377&partnerID=8YFLogxK
U2 - 10.21037/TAU-20-966
DO - 10.21037/TAU-20-966
M3 - Article
AN - SCOPUS:85100310377
VL - 10
SP - 417
EP - 425
JO - Translational Andrology and Urology
JF - Translational Andrology and Urology
SN - 2223-4683
IS - 1
ER -